A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Public ClinicalTrials.gov record NCT04700449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
Study identification
- NCT ID
- NCT04700449
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 145 participants
Conditions and interventions
Conditions
Interventions
- Double-Blind 0.2mg CBP-307 Drug
- Double-Blind Placebo Drug
- Open-label CBP-307 Drug
- Double-Blind 0.1mg CBP-307 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2019 (Actual)
- Primary completion
- Feb 23, 2022 (Actual)
- Completion
- Nov 10, 2022 (Actual)
- Last update posted
- May 6, 2024
2019 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Connect Investigative Site 2316 | Phoenix | Arizona | 85018 | — |
| Connect Investigative Site 2308 | Mission Hills | California | 91345 | — |
| Connect Investigative Site 2314 | Hialeah | Florida | 33016 | — |
| Connect Investigative Site 2309 | Homestead | Florida | 33032 | — |
| Connect Investigative Site 2320 | Kissimmee | Florida | 34741 | — |
| Connect Investigative Site 2318 | Miami | Florida | 33126 | — |
| Connect Investigative Site 2302 | Orlando | Florida | 32803 | — |
| Connect Investigative Site 2304 | Orlando | Florida | 32810 | — |
| Connect Investigative Site 2306 | Orlando | Florida | 32819 | — |
| Connect Investigative Site 2307 | Atlanta | Georgia | 30309 | — |
| Connect Investigative Site 2315 | Cincinnati | Ohio | 45219 | — |
| Connect Investigative Site 2321 | Oklahoma City | Oklahoma | 73102 | — |
| Connect Investigative Site 2311 | Cypress | Texas | 90212 | — |
| Connect Investigative Site 2319 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04700449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2024 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04700449 live on ClinicalTrials.gov.